Carelon Healthcare Services will now cover Guardant Health's Shield blood test for colorectal cancer screening, expanding commercial coverage to about 90 million eligible individuals.
Singular Genomics introduced Direct-Seq technology for in situ sequencing of FFPE samples on its G4X platform and announced the SPOT-Met colorectal cancer study at AGBT 2026, analyzing 1,000 tumors using spatial multiomics.
The collaboration has produced a custom nucleic acid extraction workflow designed to unlock molecular insights from a novel biospecimen and improve diagnostic utility in gut health conditions.
CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testing.
Read More
The collaboration will combine New Day’s liquid biopsy technology with Daisy Genomics’ physics-based sequencing platform to advance early CRC screening.
Read More
The biotechnology company’s integrated screening approach combines whole-genome sequencing, imaging, and multiple biomarker tests to enable early detection.
Read More
Circulating tumor DNA testing can identify stage 3 patients who may safely receive reduced treatment intensity, international study finds.
Read More
The company is collaborating with Guardant Health to make Guardant’s Shield test available through Quest’s nationwide network of provider clients and patient service centers.
Read More
The test provides fully automated, sample-to-result testing to identify patients eligible for immunotherapy treatment.
Read More
Personalis has expanded and extended its partnership with Tempus AI to include colorectal cancer in their NeXT Personal MRD test.
Read More
Vibrant Wellness has enhanced its Gut Zoomer microbiome panel with expanded microbial and metabolite testing.
Read More
A study found that colorectal cancer screening could be boosted by using a rapid, accurate app-read smartphone FIT.
Read More
New Day Diagnostics has launched ColoHealth, a physician-mediated blood test for colorectal cancer screening.
Read More
Natural disasters and the COVID-19 pandemic disrupted colorectal cancer diagnoses in Puerto Rico, leading to a rise in delayed diagnoses.
Read More
Sysmex America will distribute Sentinel Diagnostics SENTiFIT 270 and 800 analyzers in Canada for colorectal cancer (CRC) screening.
Read More
Mainz Biomed is collaborating with Quest Diagnostics to support the commercialization and FDA validation of a stool-based DNA test.
Read More
A new study highlights the critical role of genomic testing in diagnosing Lynch syndrome and guiding treatment for inherited cancers.
Read More
Colorectal cancer screening, while highly effective, is underutilized among patients at federally qualified health centers (FQHCs).
Read More